Volume 25, Number 9—September 2019
Research Letter
Limited Scope of Shorter Drug Regimen for MDR TB Caused by High Resistance to Fluoroquinolone
Figure

Figure. Flow diagram of participants and testing results in study of limitation of shorter treatment regimen for multidrug-resistant tuberculosis by high resistance to fluoroquinolone, Uttar Pradesh, India. *Inconclusive LPA-SLD (n = 167; 23.6% of total samples received). LPA-SLD, line-probe assay for second-line drugs; FQ, fluoroquinolones; MGIT, Mycobacterium growth indicator tube.
Page created: August 21, 2019
Page updated: August 21, 2019
Page reviewed: August 21, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.